GANX – gain therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at Roth Capital.
Gain Therapeutics (NASDAQ:GANX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
Form 8-K Gain Therapeutics, Inc. For: Dec 18
Form S-8 Gain Therapeutics, Inc.
Form 8-K Gain Therapeutics, Inc. For: Nov 28
Form 424B5 Gain Therapeutics, Inc.
Form 10-Q Gain Therapeutics, Inc. For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.